<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <ArticleTitle>Insight on development and management of diabetic neuropathy</ArticleTitle>
      <Abstract>Diabetic peripheral neuropathy (DPN) impacts up to 50% of diabetic people and is a major cause of illness and death. Its neuropathic symptoms, which can be painful, and insensitivity increase the risk of burns, injuries, and foot ulcers. A number of recent studies have identified a number of risk factors for the development of DPN, including obesity, poor glycemic control, diabetes duration, hyperlipidaemia, impaired insulin signalling, and lipid oxidation and inflammation. Inspection of the lower limbs is necessary for diagnosis. Anticonvulsant or tricyclic medications, which are typically used, may be needed. Peripheral neuropathy patients should be treated by a podiatrist and given preventative education since they are at risk of developing insensate foot ulcers. A multidisciplinary approach to the prevention and management of foot problems, the prompt diagnosis and treatment of neuropathic pain, and the control of specific cardiometabolic objectives should all be included in the therapy of patients with DPN. The concept of categorised patients based on different aspects of their pain in order to enhance analgesic response is being researched, and new drugs are being developed for the management of painful DPN.</Abstract>
      <Keywords>Hyper lipidaemia, Cardiometabolic, Sensorimotor polyneuropathy, Paraesthesia, Hyperglycemia</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14966&amp;title=Insight on development and management of diabetic neuropathy</Abstract>